Epidermal Growth Factor Enhances Striatal Dopaminergic Parameters in the 1-Methyl-4-Phenyl-l, 2, 3, 6-Tetrahydropyridine-Treated Mouse
Article first published online: 5 OCT 2006
Journal of Neurochemistry
Volume 57, Issue 2, pages 479–482, August 1991
How to Cite
Hadjiconstantinou, M., Fitkin, J. G., Dalia, A. and Neff, N. H. (1991), Epidermal Growth Factor Enhances Striatal Dopaminergic Parameters in the 1-Methyl-4-Phenyl-l, 2, 3, 6-Tetrahydropyridine-Treated Mouse. Journal of Neurochemistry, 57: 479–482. doi: 10.1111/j.1471-4159.1991.tb03776.x
- Issue published online: 5 OCT 2006
- Article first published online: 5 OCT 2006
- Received December 31, 1990; accepted January 8, 1991.
- Epidermal growth factor;
Intracerebroventricular infusion of epidermal growth factor (EOF) into mice with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced degeneration of dopaminergic nigrostriatal neurons partially enhanced the content of dopamine (DA) and 3, 4-dihydroxyphenylacetic acid as well as the activity of tyrosine hydroxylase in the striatum. EGF also enhanced these parameters in control, unlesioned animals. Neurotrophic activity also was observed in embryonic mesencephalic cultures, where EGF enhanced DA uptake after a lesion with the neurotoxic metabolite of MPTP, 1-methyl-4-phenylpyridinium ion. Our in vivo and in vitro studies suggest that EGF may be a neurotrophic factor for dopaminergic neurons, or may act indirectly by inducing the release of a dopaminergic trophic factor from other cells.